FY 2026 Results Chief Executive Officer Anne -Louise Arnett Chair Jayne Shaw SEPTEMBER 2026 BCAL Diagnostics Australian leader BCAL is a healthcare company developing breakthrough early cancer detection blood technology . Products BREASTEST plus Avantect® Pancreatic Avantect®...
Investor Presentation September 2026
Filed with ASX ·
6ix hasn’t read this filing yet.
BCAL Diagnostics Limited on 6ix
Story so far
Earlier from BCAL Diagnostics
- Meet The CEO FY 2026 Results Webinar 3 Sept 2026 at 1PM
- Appendix 4E and Annual Report to shareholders
- Appendix 4G and Corporate Governance Statement
- BCAL Takes Interest in Genetic Signatures to 18.46%
- Change in Substantial Shareholder Notice for GSS
Later from BCAL Diagnostics
- BCAL Seeks Board Change at Genetic Signatures
- Clarification of BCAL's Position in Relation to GSS
- Notice of Annual General Meeting/Proxy Form
- Letter to Shareholders re Annual General Meeting
- BCAL Introduces Avantect Multi-Cancer Early Detection Test
Follow BCAL Diagnostics into a list and get an email when it puts out news.
Follow BCAL Diagnostics